- 併存症、同時罹患率、合併性 (WebLSDより)
- Clinical manifestations of HF vary depending on the rapidity of cardiac decompensation, underlying etiology, age, and comorbidities of the patients.(WMM.168)
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2012/09/07 08:23:27」(JST)[Wiki en表示]
In medicine, comorbidity is either the presence of one or more disorders (or diseases) in addition to a primary disease or disorder, or the effect of such additional disorders or diseases.
In medicine, comorbidity describes the effect of all other diseases an individual patient might have other than the primary disease of interest.
Many tests attempt to standardize the "weight" or value of comorbid conditions, whether they are secondary or tertiary illnesses. Each test attempts to consolidate each individual comorbid condition into a single, predictive variable that measures mortality or other outcomes. Researchers have validated such tests because of their predictive value, but no one test is as yet recognized as a standard.
The term "comorbid" has two definitions:
- to indicate a medical condition existing simultaneously but independently with another condition in a patient (this is the older and more "correct" definition)
- to indicate a medical condition in a patient that causes, is caused by, or is otherwise related to another condition in the same patient (this is a newer, nonstandard definition and less well-accepted).
The Charlson co-morbidity index predicts the ten-year mortality for a patient who may have a range of co-morbid conditions such as heart disease, AIDS, or cancer (a total of 22 conditions). Each condition is assigned with a score of 1,2,3 or 6 depending on the risk of dying associated with this condition. Then the scores are summed up and given a total score which predicts mortality. There are many variations of the Charlson comorbidity index including the Charlson/Deyo, Charlson/Romano, Charlson/Manitoba, and Charlson/ D'Hoores adaptations of the Charlson comorbidity index.
The clinical conditions and scores are as follow: 1 each: Myocardial infarct, congestive heart failure, peripheral vascular disease, dementia, cerebrovascular disease, chronic lung disease, connective tissue disease, ulcer, chronic liver disease. 2 each: Hemiplegia, moderate or severe kidney disease, diabetes, diabetes with complication, tumor, leukemia, lymphoma. 3 each: Moderate or severe liver disease. 6 each: Malignant tumor, metastasis, AIDS.
For a physician, it is helpful in knowing how aggressively to treat a condition. For example, a patient may have cancer, but also heart disease and diabetes so severe that the costs and risks of the treatment outweigh the short term benefit from treatment of the cancer.
Since patients often do not know how severe their conditions are, originally to calculate the index nurses were supposed to go through the patient's chart and determine whether the patient had a particular condition. Subsequent studies have adapted it to a questionnaire for patients.
The Elixhauser comorbidity measure was developed using administrative data from a statewide California inpatient database from all non-federal inpatient community hospital stays in California (n = 1,779,167). The Elixhauser comorbidity measure developed a list of 30 comorbidities relying on the ICD-9-CM coding manual. The comorbidities were not simplified as an index because each comorbidity affected outcomes (length of hospital stay, hospital changes, and mortality) differently among different patients groups. The comorbidities identified by the Elixhauser comorbidity measure are significantly associated with in-hospital mortality and include both acute and chronic conditions. Walraven et al. has derived and validated an Elixhauser comorbidity index that summarizes disease burden and can discriminate for in-hospital mortality.
Patients who are more seriously ill tend to require more hospital resources than patients who are less seriously ill, even though they are admitted to the hospital for the same reason. Recognizing this, the diagnosis-related group (DRG) manual splits certain DRGs based on the presence of secondary diagnoses for specific complications or comorbidities (CC). The same applies to Healthcare Resource Groups (HRGs) in the UK.
In psychiatry, psychology and mental health counseling comorbidity refers to the presence of more than one diagnosis occurring in an individual at the same time. However, in psychiatric classification, comorbidity does not necessarily imply the presence of multiple diseases, but instead can reflect our current inability to supply a single diagnosis that accounts for all symptoms. On the DSM Axis I, Major Depressive Disorder is a very common comorbid disorder. The Axis II personality disorders are often criticized because their comorbidity rates are excessively high, approaching 60% in some cases, indicating to critics the possibility that these categories of mental illness are too imprecisely distinguished to be usefully valid for diagnostic purposes and, thus, for deciding how treatment resources should be allocated.
The term 'comorbidity' was introduced in medicine by Feinstein (1970) to denote those cases in which a 'distinct additional clinical entity' occurred during the clinical course of a patient having an index disease. Although the term has recently become very fashionable in psychiatry, its use to indicate the concomitance of two or more psychiatric diagnoses is said to be incorrect because in most cases it is unclear whether the concomitant diagnoses actually reflect the presence of distinct clinical entities or refer to multiple manifestations of a single clinical entity. It has been argued that because "'the use of imprecise language may lead to correspondingly imprecise thinking', this usage of the term 'comorbidity' should probably be avoided".
Due to its artifactual nature, psychiatric comorbidity has been considered as a Kuhnian anomaly leading the DSM to a scientific crisis  and a comprehensive review on the matter considers comorbidity as an epistemological challenge to modern psychiatry.
Inception of the term
Many centuries ago the doctors propagated the viability of a complex approach in the diagnosis of disease and the treatment of the patient, however modern medicine, which boasts a wide range of diagnostic methods and variety of therapeutic procedures, stresses specification. This brought up a question: How to wholly evaluate the state of a patient who suffers from a number of diseases simultaneously, where to start from and which disease(s) require(s) primary and subsequent treatment? For many years this question stood out unanswered, until 1970, when a renowned American doctor epidemiologist and researcher, A.R. Feinstein, who had greatly influenced the methods of clinical diagnosis and particularly methods used in the field of clinical epidemiology, came out with the term of “comorbidity”. The appearance of comorbidity was demonstrated by Dr. Feinstein using the example of patients physically suffering from rheumatic fever, discovering the worst state of the patients, who simultaneously suffered from multiple diseases. In due course of time after its discovery, comorbidity was distinguished as a separate scientific-research discipline in many branches of medicine.
Evolution of the term
Presently there is no agreed-upon terminology of comorbidity. Some authors bring forward different meanings of comorbidity and multi-morbidity, defining the former, as the presence of a number of diseases in a patient, connected to each other through proven pathogenetic mechanisms and the latter, as the presence of a number of diseases in a patient, not having any connection to each other through any of the proven till date pathogenetic mechanisms. Other affirm that multi-morbidity is the combination of a number of chronic or acute diseases and clinical symptoms in a person and do not stress the similarities or differences in their pathogenesis. However the principle clarification of the term was given by H. C. Kraemer and M. van den Akker, determining comorbidity, as the combination in a patient of 2 or more chronic diseases (disorders), pathogenetically related to each other or coexisting in a single patient independent of each disease’s activity in the patient.
Wide spread study of physical and mental pathology found its place in psychiatry. I. Jensen (1975), J.H. Boyd (1984), W.C. Sanderson (1990), Y. L. Nuller (1993), D.L. Robins (1994), A. B. Smulevich (1997), C.R. Cloninger (2002) and other renowned psychiatrists devoted many years for the discovery of a number of comorbid conditions in patients suffering from most diverse psychiatric disorders. These very researchers developed the first models of comorbidity. Some of the models studied comorbidity as the presence in a person (patient) of more than one disorders (diseases) at a certain period of life, whereas the others elaborated the relative risk, for a person having one disease, of picking up other disorders.
The influence of comorbidity on the clinical progression of the primary (basic) physical disorder, effectiveness of the medicinal therapy and immediate and long-term prognosis of the patients was researched by talented physicians and scientists of various medical fields in many countries across the globe. These scientists and physicians included: M.H. Kaplan (1974), T. Pincus (1986), M.E. Charlson (1987), F.G. Schellevis (1993), H.C.Kraemer (1995), M. van den Akker (1996), A. Grimby (1997), S. Greenfield (1999), M. Fortin (2004) и A. Vanasse (2004), C. Hudon (2005), L. B. Lazebnik (2005), A. L.Vertkin (2008), G.E. Caughey (2008), F. I. Belyaov (2009), L. A. Luchikhin (2010) and many others.
Synonyms of comorbidity
- Multifactorial diseases
- Dual diagnosis, used for mental health issues
Epidemiology of comorbidity
Comorbidity is wide spread among the patients admitted at multidiscipline hospitals. During the phase of initial medical help, the patients having multiple diseases simultaneously are a norm rather than an exception. Prevention and treatment of chronic diseases declared by the World Health Organization (WHO), as a priority project for the second decade of the 20th century, are meant to better the quality of the global population. This is the reason for an overall tendency of large-scale epidemiological researches in different medical fields, carried-out using serious statistical data. In most of the carried-out, randomized, clinical researches the authors study patients with single refined pathology, making comorbidity an exclusive criterion. This is why it is hard to relate researches, directed towards the evaluation of the combination of ones or the other separate disorders, to works regarding the sole research of comorbidity. The absence of a single scientific approach to the evaluation of comorbidity leads to omissions in clinical practice. It is hard not to notice the absence of comorbidity in the taxonomy (systematics) of disease, presented in the International classification of disease 10th edition.
The role of clinico-pathological comparison in the study of comorbidity
All the fundamental researches of medical documentation, directed towards the study of the spread of comorbidity and influence of its structure, were conducted till the 1990s. The sources of information, used by the researchers and scientists, working on the matter of comorbidity, were case histories, hospital records of patients and other medical documentation, kept by family doctors, insurance companies and even in the archives of patients in old houses.
The listed methods of obtaining medical information are mainly based on clinical experience and qualification of the physicians, carrying out clinically, instrumentally and laboratorially confirmed diagnosis. This is why despitetheir competence, they are highly subjective. No analysis of the results of postmortem of deceased patients was carried out for any of the comorbidity researches.
"It is the duty of the doctor to carry out autopsy of the patients they treat", said once professor M. Y. Mudrov. Autopsy allows you to exactly determine the structure of comorbidity and the direct cause of death of each patient independent of his/her age, gender and gender specific characteristics. Statistical data of comorbid pathology, based on these sections, are mainly devoid of subjectivism.
Research of comorbidity
The analysis of a decade long Australian research based on the study of patients having 6 wide spread chronic diseases demonstrated that nearly half of the aged patients with arthritis also had hypertension, 20% had cardiac disorders and 14% had type 2 diabetes. More than 60% of asthmatic patients complained of concurrent arthritis, 20% complained of cardiac problems and 16% had type 2 diabetes.
In aged patients with chronic nephatony the frequency of coronary heart diseases is 22% higher and new coronary events are 3.4 times higher as compared to patients without kidney function disorders. During the progression of ESRF, requiring substitutive therapy, the frequency of chronic forms of CHD is 24.8% and of cardiac accident is 8.7%.
A Canadian research conducted upon 483 obesity patients, it was determined that spread of obesity related accompanying diseases was higher among females than males. The researchers discovered that nearly 75% of obesity patients had accompanying diseases, which mostly included dyslipidemia, hypertension and type 2 diabetes.It is to be noted that among the young obesity patients (from 18 to 29) more than two chronic diseases were found in 22% males and 43% females.
Fibromyalgia is a condition which is comorbid with several others, including but not limited to; depression, anxiety, headache, irritable bowel syndrome, chronic fatigue syndrome, systemic lupus erythematosus, rheumatoid arthritis , migraine, and panic disorder.
The number of comorbid diseases increases with age. Comorbidity increases by 10% in ages up to 19 years, up to 80% in people of ages 80 and older. According to data by M. Fortin, based on the analysis of 980 case histories, taken from daily practice of a family doctor, the spread of comorbidity is from 69% in young patients, up to 93% among middle aged people and up to 98% patients of older age groups. At the same time the number of chronic diseases varies from 2.8 in young patients and 6.4 among older patients.
According to Russian data, based on the study of more than three thousand postmortem reports (n=3239) of patients of physical pathologies, admitted at multidisciplinary hospitals for the treatment of chronic disorders (average age 67.8 ± 11.6 years), the frequency of comorbidity is 94.2%. Doctors mostly come across a combination of two to three disorders, but in rare cases (up to 2.7%) a single patient carried a combination of 6–8 diseases simultaneously.
The fourteen year long research conducted on 883 patients of idiopathic idiopathic thrombocytopenic purpura (Werlhof disease), conducted in Great Britain, shows that the given disease is related to a wide range of physical pathologies. In the comorbid structure of these patients, most frequently present are malignant neoplasms, locomotorium disorders, skin and genitourinary system disorders, as well as haemorrhagic complications and other autoimmune diseases, the risk of whose progression during the first five years of the primary disease exceeds the limit of 5%.
In a research conducted on 196 larynx cancer patients, it was determined that the survival rate of patients at various stages of cancer differs depending upon the presence or absence of comorbidity. At the first stage of cancer the survival rate in the presence of comorbidity is 17% and in its absence it is 83%, in the second stage of cancer the rate of survivability is 14% and 76%, in the third stage it is 28% and 66% and in the fourth stage of cancer it is 0% and 50% respectively. Overall the survivability rate of comorbid larynx cancer patients is 59% lower than the survivability rate of patients without comorbidity.
Except for therapists and general physicians, the problem of comorbidity is also often faced by specialists. Regretfully they seldom pay attention to the coexistence of a whole range of disorders in a single patient and mostly conduct the treatment of specific to their specialization diseases. In current practice urologists, gynecologists, ENT specialists, eye specialists, surgeons and other specialists all too often mention only the diseases related to “own” field of specialization, passing on the discovery of other accompanying pathologies “under the control” of other specialists. It has become an unspoken rule for any specialized department to carry out consultations of the therapist, who feels obliged to carry out symptomatic analysis of the patient, as well as the to form the diagnostic and therapeutic concept, taking in view the potential risks for the patient and his long-term prognosis.
Based on the available clinical and scientific data it is possible to conclude that comorbidity has a range of undoubted properties, which characterize it as a heterogeneous and often encountered event, which enhances the seriousness of the condition and worsens the patient’s prospects. The heterogeneous character of comorbidity is due to the wide range of reasons causing it.
Causes of comorbidity
- Anatomic proximity of diseased organs
- Singular pathogenetic mechanism of a number of diseases
- Terminable cause-effect relation between the diseases
- One disease resulting from complications of another
- Pleiotropy 
The factors responsible for the development of comorbidity can be chronic infections, inflammations, involutional and systematic metabolic changes, iatrogenesis, social status, ecology and genetic susceptibility.
Types of comorbidity
- Trans-syndromal comorbidity: coexistence, in a single patient, of two and/or more syndromes, pathogenetically related to each other.
- Trans-nosological comorbidity: coexistence, in a single patient, of two and/or more syndromes, pathogenetically related to each other.
The division of comorbidity as per syndromal and nosological principles is mainly preliminary and inaccurate, however it allows us to understand that comorbidity can be connected to a singular cause or common mechanisms of pathogenesis of the conditions, which sometimes explains the similarity in their clinical aspects, which makes it difficult to differentiate between nosologies.
- Etiological comorbidity: It is caused by concurrent damage to different organs and systems, which is caused by a singular pathological agent (for example due to alcoholism in patients suffering from chronic alcohol intoxication; pathologies associated with smoking; systematic damage due to collagenoses).
- Complicated comorbidity: It is the result of the primary disease and often subsequent after sometime after its destabilization appears in the shape of target lesions (for example chronic nephatony resulting from diabetic nephropathy (Kimmelstiel-Wilson disease) in patients with type 2 diabetes; development of brain infarction resulting from complications due to hypertensive crisis in patients suffering from hypertension).
- Iatrogenic comorbidity: It appears as a result of necessitated negative effect of the doctor on the patient, under the conditions of pre determine danger of one or the other medical procedure (for example, glucocorticosteroid osteoporosis in patients treated for a long time using systematic hormonal agents (preparations); drug-induced hepatitis resulting from chemotherapy against TB, prescribed due to the conversion of tubercular tests).
- Unspecified (NOS) comorbidity: This type assumes the presence of singular pathogenetic mechanisms of development of diseases, comprising this combination, but require a number of tests, proving the hypothesis of the researcher or physician (for example, erectile dysfunction as an early sign of general atherosclerosis (ASVD); occurrence of erosive-ulcerative lesions in the mucous membrane of the upper gastrointestinal tract in “vascular” patients).
- “Arbitrary”comorbidity: initial alogism of the combination of diseases is not proven, but soon can be explained with clinical and scientific point of view (for example, combination of coronary heart disease (CHD) and choledocholithiasis; combination of acquired heart valvular disease and psoriasis).
Structure of comorbidity
There are a number of rules for the formulation of clinical diagnosis for comorbid patients, which must be followed by a practitioner. The main principle is to distinguish in diagnosis the primary and background diseases, as well as their complications and accompanying pathologies.
- Primary disease: This is the nosological form, which itself or as a result of complications calls for the foremost necessity for treatment at the time due to threat to the patient’s life and danger of disability. Primary is the disease, which becomes the cause of seeking medical help or the reason for the patient’s death. If the patient has several primary diseases it is important to first of all understand the combined primary diseases (rival or concomitant).
- Rival diseases: These are the concurrent nosological forms in a patient, interdependent in etiologies and pathogenesis, but equally sharing the criterion of a primary disease (for example, transmural myocardial infarction and massive thromboembolism of pulmonary artery, caused by phlebemphraxis of lower limbs). For practicing pathologist rival are two or more diseases, exhibited in a single patient, each of which by itself or through its complications could cause the patient’s death.
- Polypathia: Diseases with different etiologies and pathogenesis, each of which separately could not cause death, but, concurring during development and reciprocally exacerbating each other, they cause the patient’s death (for example, osteoporotic fracture of the surgical neck of the femur and hypostatic pneumonia).
- Background disease: This helps in the occurrence of or adverse development of the primary disease increases its dangers and helps in the development of complications. This disease as well as the primary one requires immediate treatment (for example, type 2 diabetes).
- Complications: Nosologies having pathogenetic relation to the primary disease, supporting the adverse progression of the disorder, causing acute worsening of the patient’s conditions (are a part of the complicated comorbidity). In a number of cases the complications of the primary disease and related to it etiological and pathogenetic factors, are indicated as conjugated disease. In this case they must be identified as the cause of comorbidity. Complications are listed in a descending order of prognostic or disabling significance.
- Associating diseases: Nosological units not connected etiologically and pathogenetically with the primary disease (Listed in the order of significance).
Diagnosis of comorbidity
There is no doubt in the significance of comorbidity, but how to evaluate (measure) it in a given patient?
Patient S., 73 years, called an ambulance because of a sudden pressing pain in the chest. It was known from the case history that the patient suffered from CHD for many years. Such chest pains were experienced by her earlier as well, but they always disappeared after a few minutes of sublingual administration of organic nitrates. This time taking three tablets of nitroglycerine did not kill the pain. It was also known from the case history that the patient had twice suffered during the last ten years from myocardial infarction, as well as from Acute Cerebrovascular Event with sinistral hemiplegia more than 15 years ago. Apart from that the patient suffers from hypertension, type 2 diabetes with diabetic nephropathy, hysteromyoma, cholelithiasis, osteoporosis and varicose pedi-vein disease. It also came to knowledge that the patient regularly takes a number of antihypertensive drugs, urinatives and oral antihyperglycemic remedies, as well as statins, antiplatelet and nooptropics. In the past the patient had undergone cholecystectomy due to cholelithiasis more than 20 years ago, as well as the extraction of crystalline humor due to cataract of the right eye 4 years ago. The patient was admitted to cardiac intensive care unit at a general hospital diagnosed for acute transmural myocardial infarction. During the check-up moderate azotemia, mild erythronormoblastic anemia, proteinuria and lowering of left vascular ejection fraction were also identified.
Methods of evaluation of comorbidity
There are currently several generally accepted methods of evaluating (measuring) comorbidity:
- Cumulative Illness Rating Scale (CIRS): Developed in 1968 by B. S. Linn, it became a revolutionary discovery, because it gave the practicing doctors a chance to calculate the number and severity of chronic illnesses in the structure of the comorbid state of their patients. The proper use of CIRS means separate cumulative evaluation of each of the biological systems: “0” The selected system corresponds to the absence of disorders, “1”: Slight (mild) abnormalities or previously suffered disorders, “2”: Illness requiring the prescription of medicinal therapy, “3”: Disease, which caused disability and “4”: Acute organ insufficiency requiring emergency therapy. The CIRS system evaluates comorbidity in cumulative score, which can be from 0 to 56. As per its developers, the maximum score is not compatible with the patient’s life. This way patients S’s comorbidity in 73 years of age can be evaluated as of moderate severity (23 points out of 56), however it is not possible to evaluate the prognosis of the patient, because of the absence of the interpretation of the acquired results their connection with a number of prognostic characteristics..
- Cumulative Illness Rating Scale for Geriatrics (CIRS-G): This system is similar to CIRS, but for aged patients, offered by M. D. Miller in 1991. This system takes into account the age of the patient and the peculiarities of the old age disorders.
- The Kaplan-Feinstein Index: This index was created in 1973 based on the study of the effect of the associated diseases on patients suffering from type 2 diabetes during a period of 5 years. In this system of comorbidity evaluation all the present (in a patient) diseases and their complications, depending on the level of their damaging effect on body organs, are classified as mild, moderate and severe. In this case the conclusion about cumulative comorbidity is drawn on the basis of the most decompensated biological system. This index gives cumulative, but less detailed as compared to CIRS, assessment of the condition of each of the biological systems: “0”: Absence of disease, “1”: Mild course of the disease, “2”: Moderate disease, “3”: Severe disease. The Kaplan-Feinstein Index evaluates comorbidity by cumulative score, which can vary from 0 to 36. Apart from that the notable deficiency of this method of evaluating comorbidity is the excessive generalization of diseases (nosologies) and the absence of a large number of illnesses in the scale, which, probably, should be noted in the “miscellaneous” column, which undermines (decreases) this method’s objectivity and productivity of this method. However the indisputable advantage of the Kaplan-Feinstein Index as compared to CIRS is in the capability of independent analysis of malignant neoplasms and their severities. Using this method patient S’s, age 73, comorbidity can be evaluated as of moderate severity (16 out of 36 points), however its prognostic value is unclear, because of the absence of the interpretation of the overall score, resulting from the accumulation of the patient’s diseases.
- Charlson Index: This index is meant for the long-term prognosis of comorbid patients and was developed by M. E. Charlson in 1987. This index is based on a point scoring system (from 0 to 40) for the presence of specific associated diseases and is used for prognosis of lethality. For its calculation the points are accumulated, according to associated diseases, as well as the addition of a single point for each 10 years of age for patients of ages above forty years (in 50 years 1 point, 60 years 2 points etc.). The distinguishing feature and undisputed advantage of the Charlson Index is the capability of evaluating the patient’s age and determination of the patient’s mortality rate, which in the absence of comorbidity is 12%, at 1–2 points it is 26%; at 3–4 points it is 52% and with the accumulation of more than 5 points it is 85%. Regretfully this method has some deficiencies: Evaluating comorbidity severity of many diseases is not considered, as well as the absence of many important for prognosis disorders. Apart from that it is doubtful that possible prognosis for a patient suffering from bronchial asthma and chronic leukemia is comparable to the prognosis for the patient ailing from myocardial infarction and cerebral infarction. In this case comorbidity of patient S, 73 years of age according to this method, is equivalent to mild state (9 out of 40 points).
- Modified Charlson Index: R. A. Deyo added chronic forms of ischemic cardiac disorder and the stages of chronic cardiac insufficiency to this index in 1992.
- Index of Co-Existent Disease (ICED): This Index was first developed in 1993 by S. Greenfield to evaluate comorbidity in patients with malignant neoplasms, but was later it also became useful for other categories of patients. This method helps in calculating the duration of a patient’s stay at a hospital and the risks of repeated admittance of the same at a hospital after going through surgical procedures. For the evaluation of comorbidity the ICED index suggests to evaluate the patient’s condition separately as per two different components: Physiological functional characteristics. The first component comprises 19 associated disorders, each of which is assessed on a 4 point scale, where “0” indicates the absence of disease and “3” indicates the disease’s severe form. The second component evaluates the effect of associated diseases on the physical condition of the patient. It assesses 11 physical functions using a 3 point scale, where “0” means normal functionality and “2” means the impossibility of functionality.
- Geriatric Index of Comorbidity (GIC): Developed in 2002
- Functional Comorbidity Index (FCI): Developed in 2005.
- Total Illness Burden Index (TIBI): Developed in 2007.
Analyzing the comorbid state of patient S, 73 years of age, using the most used international comorbidity assessment scales, a doctor would come across totally different evaluation. The uncertainty of these results would somewhat complicate the doctors judgment about the factual level of severity of the patient’s condition and would complicate the process of prescribing rational medicinal therapy for the identified disorders. Such problems are faced by doctors on everyday basis, despite all their knowledge about medical science. The main hurdle in the way of inducting comorbidity evaluation systems in broad based diagnostic-therapeutic process is their inconsistency and narrow focus. Despite the variety of methods of evaluation of comorbidity, the absence of a singular generally accepted method, devoid of the deficiencies of the available methods of its evaluation, causes disturbance. The absence of a unified instrument, developed on the basis of colossal international experience, as well as the methodology of its use does not allow comorbidity to become doctor “friendly”. At the same time due to the inconsistency in approach to the analysis of comorbid state and absence of components of comorbidity in medical universitycourses, the practitioner is unclear about its prognostic effect, which makes the generally available systems of associated pathology evaluation unreasoned and therefore un-needed as well.
Models of comorbidity
Treatment of comorbid patient
The effect of comorbid pathologies on clinical implications, diagnosis, prognosis and therapy of many diseases is polyhedral and patient-specific. The interrelation of the disease, age and drug pathomorphism greatly affect the clinical presentation and progress of the primary nosology, character and severity of the complications, worsens the patient’s life quality and limit or make difficult the remedial-diagnostic process. Comorbidity effects life prognosis and increases the chances of fatality. The presence of comorbid disorders increase bed days, disability, hinders rehabilitation, increases the number of complications after surgical procedures and enhances the chances of decline in aged people.
The presence of comorbidity must be taken into account when selecting the algorithm of diagnosis and treatment plans for any given disease. It is important to enquire comorbid patients about the level of functional disorders and anatomic status of all the identified nosological forms (diseases). Whenever a new, as well as mildly notable symptom appears, it is necessary to conduct a deep examination to uncover its causes. It is also necessary to be remembered that comorbidity leads to polypragmasy, i.e. simultaneous prescription of a large number of medicines, which renders impossible the control over the effectiveness of the therapy, increases monetary expenses and therefore reduces compliance. At the same time, polypragmasy, especially in aged patients, renders possible the sudden development of local and systematic, unwanted medicinal side-effects. These side-effects are not always considered by the doctors, because they are considered as the appearance of comorbidity and as a result become the reason for the prescription of even more drugs, sealing-in the vicious circle. Simultaneous treatment of multiple disorders requires strict consideration of compatibility of drugs and detailed adherence of rules of rational drug therapy, based on E. M. Tareev’s principles, which state: “Each non-indicated drug is contraindicated” and B. E. Votchal said: “If the drug does not have any side-effects, one must think if there is any effect at all”.
- Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M (2009). "Defining comorbidity: implications for understanding health and health services.". Annals of Family Medicine 7 (4): 357–63. doi:10.1370/afm.983. PMC 2713155. PMID 19597174. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2713155/.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis, 40(5): 373–383.
- First MB (2005). "Mutually exclusive versus co-occurring diagnostic categories: the challenge of diagnostic comorbidity". Psychopathology 38 (4): 206–10. doi:10.1159/000086093. PMID 16145276.
- 'Psychiatric comorbidity': an artefact of current diagnostic systems?
- Aragona M. The Role of Comorbidity in the Crisis of the Current Psychiatric Classification System // Philosophy, Psychiatry, & Psychology. 2009 March; 16(1):1–11
- Jakovljević M., Crnčević Z. Comorbidity as an epistemological challenge to modern psychiatry// Dialogues in Philosophy, Mental and Neuro Sciences. 2012 June; 5(1): 1–13
- Feinstein A.R. Pre-therapeutic classification of co-morbidity in chronic disease // Journal Chronic Disease, 1970; 23(7):455–468
- Лазебник Л. Б. Старение и полиморбидность // Консилиум Медикум, 2005, № 12
- Greenfield S., Apolone G., McNeil B.J., Cleary P.D. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement // Med Care. 1993 Feb;31(2):141–154
- Jensen I. Proceedings: Pathology and prognostic factors in temporal lobe epilepsy. Follow-up after temporal lobe resection // Acta Neurochir , 1975; 31(3–4):261–2
- Boyd J.H., Burke J.D. Exclusion criteria of DSM-III: a study of co-occurrence of hierarchy-free syndromes // Arch Gen Psychiatry, 1984; 41: 983–9
- Sanderson W.C., Beck A.T., Beck J. Syndrome comorbidity in patients with major depression or dysthymia: Prevalence and temporal relationships // Am J Psychiatry, 1990; 147:10-25-1028
- Нуллер Ю. Л. Обзор психиатрии и медицинской психологии // Москва,1993; 1:29–37
- Robins D.L. How recognizing comorbidities in psychopathology may lead to an improved research nosology // Clinical Psychology: Science and Practice, 1994; 1, 93–95
- Смулевич А. Б., Дубницкая Э. Б., Тхостов А. Ш. Депрессии и коморбидные расстройства // Москва, 1997
- Cloninger C.R. Implications of comorbidity for the classification of mental disorders: the need for a psychobiology of coherence // Psychiatric Diagnosis and Classification, 2002; pp. 79–105
- Kaplan M.H, Feinstein A.R. The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus // Journal Chronic Disease, 1974; 27:387–404, 1974
- Pincus T., Callahan L.F. Taking mortality in rheumatoid arthritis seriously: Predictive markers, socioeconomic status and comorbidity // J. Rheumatol, 1986; Vol.13, P.841–845
- Charlson M.E., Sax F.L. The therapeutic efficacy of critical care units from two perspectives: a traditional cohort approach vs a new case-control methodology // J Chronic Dis. 1987;40(1):31–9
- Schellevis F.G., Velden J. vd, Lisdonk E. vd Comorbidity of chronic diseases in general practice // J Clin Epidemiol, 1993; 46:469–473
- Kraemer H.C. Statistical issues in assessing comorbidity // Stat Med, 1995; 14:721–723
- van den Akker M., Buntinx F., Roos S., Knottnerus J.A.. Comorbidity or multimorbidity: what’s in a name? A review of the literature // Eur J Gen Pract, 1996; 2(2):65–70
- Grimby A., Svanborg A. Morbidity and health-related quality of life among ambulant elderly citizens // Aging, 1997; 9:356–364
- Stier D.M., Greenfield S., Lubeck D.P., Dukes K.A., Flanders S.C., Henning J.M., Weir J., Kaplan S.H. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer // Urology, 1999; Sep; 54(3):424–9
- Fortin M., Lapointe L., Hudon C., Vanasse A., Ntetu A.L., Maltais D. Multimorbidity and quality of life in primary care: a systematic review // Health Qual Life Outcomes. 2004 Sep 20;2:51
- Hudon C., Fortin M., Lapointe L., Vanasse A. Multimorbidity in medical literature: Is it commonly researched? // Can Fam Physician, 2005; 51:244–245
- Лазебник Л. Б. Полиморбидность и старение // Новости медицины и фармации 1(205), 2007
- Вёрткин А. Л., Зайратьянц О. В., Вовк Е. И. Окончательный диагноз // Москва, 2008
- Caughey G.E., Vitry A.I., Gilbert A.L., Roughead E.E. Prevalence of comorbidity of chronic diseases in Australia // BMC Public Health, 2008; 8:221
- Белялов Ф. И. Лечение внутренних болезней в условиях коморбидности // Монография; 2-е изд., Иркутск, 2010
- Лучихин Л. А. Коморбидность в ЛОР-практике // Вестник оториноларингологии, 2010; № 2, С.79–82
- Starfield B., Lemke K.W., Bernhardt T. Comorbidity: Implications for the Importance of Primary Care in Case Management // Ann Fam Med, 2003; 1(1):8–14
- van Weel C., Schellevis F.G. Comorbidity and guidelines: conflicting interests // Lancet, 2006; 367:550–551
- Gill T., Feinstein A.R. A critical appraisal of the quality-of-life measurements // JAMA, 1994; 272:619–626
- DCCT Research Group Reliability and validity of a diabetes quality of life measure for the diabetes control and complications trial (DCCT) // Diabetes Care, 1998; 11:725–732
- Michelson H., Bolund C., Brandberg Y. Multiple chronic health problems are negatively associated with health related quality of life (HRQOL) irrespective of age // Qual Life Res, 2000; 9:1093–1104
- Hoffman C., Rice D., Sung H.Y. Persons with chronic conditions. Their prevalence and costs // JAMA, 1996; 13;276(18):1473–9
- Fuchs Z., Blumstein T., Novikov I. Morbidity, comorbidity, and their association with disability among community-dwelling oldest in Israel // J Gerontol A Biol Sci Med Sci. 1998; 53A(6):M447–M455
- Daveluy C., Pica L., Audet N. Enquête Sociale et de Santé 1998. 2nd ed. Québec: Institut de la statistique du Québec; 2001
- Wolff J.L., Starfield B., Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in elderly // Arch Inter Med, 2002; 162:2269–2276
- Cuijpers P., van Lammeren P., Duzijn B. Relation between quality of life and chronic illnesses in elderly living in residential homes: a prospective study // Int Psychogeriatr, 1999; 11:445–454
- Caughey G.E., Ramsay E.N., Vitry A.I., Gilbert A.L., Luszcz M.A., Ryan P., Roughead E.E. Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study // J Epidemiol Community Health. 2010 Dec;64(12):1036–42
- Aronow W.S., Ahn C., Mercando A.D., Epstein S. Prevalence of CAD, complex ventricular arrhythmias, and silent myocardial ischemia and incidence of new coronary events in older persons with chronic renal insufficiency and with normal renal function // Am J Card, 2000; 86:1142–1143
- Bruce S.G., Riediger N.D., Zacharias J.M., Young T.K. Obesity and obesity-related comorbidities in a Canadian First Nation population // Prev Chronic Dis. 2011 Jan;8(1):A03
- Weir PT, Harlan GA, Nkoy FL, Jones SS, Hegmann KT, Gren LH, Lyon JL. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. //http://www.ncbi.nlm.nih.gov/pubmed/16755239
- Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. //http://www.ncbi.nlm.nih.gov/pubmed/1558082
- van den Akker M., Buntinx F., Metsemakers J.F., Roos S., Knottnerus J.A. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases // J Clin Epidemiol, 1998; 51:367–375
- Fortin M., Bravo G., Hudon C., Vanasse A., Lapointe L. Prevalence of multimorbidity among adults seen in family practice // A nn Fam Med, 2005; 3:223–8
- Вёрткин А. Л., Скотников А. С. Роль хронического аллергического воспаления в патогенезе бронхиальной астмы и его рациональная фармакотерапия у пациентов с полипатией // Лечащий врач, 2009; № 4, стр. 61–67
- Feudjo-Tepie M.A., Le Roux G., Beach K.J., Bennett D., Robinson N.J. Comorbidities of Idiopathic Thrombocytopenic Purpura: A Population-Based Study // Advances in Hematology, 2009;2009:963506
- Taylor V.M., Anderson G.M., McNeney B., Diehr P., Lavis J.N., Deyo R.A., Bombardier C., Malter A., Axcell T. Hospitalizations for back and neck problems: a comparison between the Province of Ontario and Washington State // Health Serv Res. 1998 Oct;33(4 Pt 1):929–45
- Zhang M., Holman C.D., Price S.D., et al. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study // BMJ, 2009; 338:a2752
- Wang P.S., Avorn J., Brookhart M.A. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives // Hypertension, 2005; 46(2):273–279
- Tomblin J.B., Mueller K.L. How can comorbidity with attention-deficit/hyperactivity disorder aid understanding of language and speech disorders? Topics in Language Disorders, 2012; July/September vol. 32,issue 3, p. 198-206
- Gijsen R., Hoeymans N., Schellevis F.G., Ruwaard D., Satariano W.A. Causes and consequences of comorbidity: a review // J Clin Epidemiol, 2001; July vol. 54, issue 7, p. 661—674
- Пальцев М. А., Автандилов Г. Г., Зайратьянц О. В., Кактурский Л. В., Никонов Е.Л. Оформление диагноза // Москва, 2006
- Зайратьянц О. В., Кактурский Л. В. Формулировка и сопоставление клинического и патологоанатомического диагнозов // Москва, 2008
- de Groot V., Beckerman H., Lankhorst G.J., Bouter L.M. How to measure comorbidity: a critical review of available methods // J Clin Epidemiol, 2003; Mar;56(3):221–9
- Linn B.S., Linn M.W., Gurel L. Cumulative illness rating scale // J Amer Geriatr Soc 1968; 16:622–626
- Miller M.D., Towers A. Manual of Guidelines for Scoring the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) // Pittsburg, Pa: University of Pittsburgh; 1991
- Miller M.D., Paradis C.F., Houck P.R., Mazumdar S., Stack J.A., Rifai A.H. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale // Psychiatry Res, 1992; 41:237e48
- Kaplan M.H., Feinstein A.R. Acritique of methods in reported studies of long-term vascular complications in patients with diabetes mellitus // Diabetes; 22(3):160–174, 1973
- Charlson M.E., Pompei P., Ales H.L. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation // Journal Chronic Disease, 1987; 40:373–383
- Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases // J Clin Epidemiol, 1992; Jun;45(6):613–9
- Rozzini R., Frisoni G.B., Ferrucci L., Barbisoni P., Sabatini T., Ranieri P., Guralnik J.M., Trabucchi M. Geriatric Index of Comorbidity: validation and comparison with other measures of comorbidity // Age Ageing, 2002; Jul;31(4):277–85
- Grolla D.L., Tob T., Bombardierc C., Wright J.G. The development of a comorbidity index with physical function as the outcome // J Clin Epidemiol, 2005; June; volume 58, issue 6, p. 595–602
- Litwin M.S., Greenfield S., Elkin E.P., Lubeck D.P., Broering J.M., Kaplan S.H. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice // Cancer 2007 May 1;109(9):1777–83
- Munoz E., Rosner F., Friedman R., Sterman H., Goldstein J., Wise L. Financial risk, hospital cost, complications and comorbidities in medical non-complications and comorbidity-stratified diagnosis-related groups // Am J Med, 1988; 84(5):933–9
Elixhauser A, Steiner C, Harris R, Coffey R. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.
Walraven CV, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47:626–33.
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 複数の併存疾患のマネージメント managing multiple comorbidities
- 2. プライマリケア医および腫瘍専門医のための癌生存ケアの概要 overview of cancer survivorship care for primary care and oncology providers
- 3. Anesthesia for the patient on dialysis
- 4. 頸動脈内膜剥離術および頸動脈ステント留置術の麻酔 anesthesia for carotid endarterectomy and carotid stenting
- 5. Preanesthesia consultation for renal transplant recipients
- Long-term prognosis and causes of death after spondylodiscitis: A Danish nationwide cohort study.
- Aagaard T1,2, Roed C1,2, Dahl B3, Obel N1.
- Infectious diseases (London, England).Infect Dis (Lond).2016 Mar;48(3):201-8. doi: 10.3109/23744235.2015.1103897. Epub 2015 Oct 20.
- BACKGROUND: Data on long-term prognosis after spondylodiscitis are scarce. The purpose of this study was to determine long-term mortality and the causes of death after spondylodiscitis.METHODS: A nationwide, population-based cohort study using national registries of patients diagnosed with non-post-
- PMID 26484577
- Negative autobiographical memories in social anxiety disorder: A comparison with panic disorder and healthy controls.
- O'Toole MS1, Watson LA2, Rosenberg NK3, Berntsen D2.
- Journal of behavior therapy and experimental psychiatry.J Behav Ther Exp Psychiatry.2016 Mar;50:223-30. doi: 10.1016/j.jbtep.2015.09.008. Epub 2015 Sep 15.
- BACKGROUND AND OBJECTIVES: Empirical interest in mental imagery in social anxiety disorder (SAD) has grown over the past years but still little is known about the specificity to SAD. The present study therefore examines negative autobiographical memories in participants with social anxiety disorder
- PMID 26412293
- Attentional blink impairment in social anxiety disorder: Depression comorbidity matters.
- Morrison AS1, Brozovich FA2, Lakhan-Pal S2, Jazaieri H3, Goldin PR4, Heimberg RG5, Gross JJ2.
- Journal of behavior therapy and experimental psychiatry.J Behav Ther Exp Psychiatry.2016 Mar;50:209-14. doi: 10.1016/j.jbtep.2015.08.006. Epub 2015 Aug 28.
- BACKGROUND AND OBJECTIVES: Difficulties with attentional control have long been thought to play a key role in anxiety and depressive disorders. However, the nature and extent of attentional control difficulties in social anxiety disorder (SAD) are not yet well understood. The current study was desig
- PMID 26370394
- 睡眠呼吸障害と併存疾患のバイオマーカー (今月の特集 知っておくべき睡眠呼吸障害のあれこれ)
- 藤本 圭作
- 臨床検査 58(3), 368-371, 2014-03
- NAID 40019989412
- 一般病院での認知症身体合併症治療はどこまで可能なのか : 国立長寿医療研究センター認知症病棟での経験
- 服部 英幸,鷲見 幸彦,櫻井 孝 [他]
- 老年精神医学雑誌 25(2), 185-192, 2014-02
- NAID 40020012977
- 高齢者造血器腫瘍治療の特徴と治療選択 (特集 CGAを考慮した高齢者に対するがん治療の特性と適応)
- 小林 幸夫
- 腫瘍内科 13(2), 244-249, 2014-02
- NAID 40020012694
- comorbidity 【名】共存症、併存疾患 - アルクがお届けする進化するオンライン英和・和英辞書データベース。一般的な単語や連語から、イディオム、専門用語、スラングまで幅広く収録。
- What Is Comorbidity? The term “comorbidity” describes two or more disorders or illnesses occurring in the same person. They can occur at the same time or one after the other. Comorbidity also implies interactions between the ...
- however, given the morbidity than can accompany this procedure, it is usually reserved for the patient who has failed 2-4 weeks of empirical therapy.(HIM.1183)